-
Something wrong with this record ?
PCSK9 Inhibitors in Real-world Practice: Analysis of Data from 314 Patients and 2 Years of Experience in a Center of Preventive Cardiology
T. Altschmiedová, V. Todorovová, M. Šnejdrlová, M. Šatný, R. Češka
Language English Country United States
Document type Journal Article, Review
- MeSH
- Anticholesteremic Agents * pharmacology therapeutic use MeSH
- Antibodies, Monoclonal, Humanized pharmacology MeSH
- Cardiology * MeSH
- Cardiovascular Diseases * prevention & control MeSH
- Humans MeSH
- PCSK9 Inhibitors MeSH
- Proprotein Convertase 9 metabolism MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Review MeSH
PURPOSE OF REVIEW: PCSK9 inhibitors have been shown to be the most effective class of drugs modifying the levels of LDL-cholesterol as the main risk factor for atherosclerotic cardiovascular disease. The aim of this paper is to assess the effect of monoclonal antibodies on lipid and lipoprotein metabolism in real-world practice. RECENT FINDINGS: The outcome trials showed effective reduction of LDL-C by 56-62%. Landmark studies enrolling over a total of 46,000 patients with CHD in their medical history demonstrated the beneficial effect of both agents on cardiovascular morbidity and mortality. The data from real everyday clinical practice are very limited or missing. Even in real-world practice, PCSK9 inhibitors have been shown to be an effective, safe, and well-tolerated class of drugs with effects comparable with those reported from large randomized controlled trials.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22018535
- 003
- CZ-PrNML
- 005
- 20220804134836.0
- 007
- ta
- 008
- 220720s2022 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s11883-022-01008-8 $2 doi
- 035 __
- $a (PubMed)35332442
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Altschmiedová, Tereza $u Center of Preventive Cardiology, 3rd Department of Internal Medicine, General University Hospital, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic. Tereza.Altschmiedova@vfn.cz $1 https://orcid.org/0000000188908643
- 245 10
- $a PCSK9 Inhibitors in Real-world Practice: Analysis of Data from 314 Patients and 2 Years of Experience in a Center of Preventive Cardiology / $c T. Altschmiedová, V. Todorovová, M. Šnejdrlová, M. Šatný, R. Češka
- 520 9_
- $a PURPOSE OF REVIEW: PCSK9 inhibitors have been shown to be the most effective class of drugs modifying the levels of LDL-cholesterol as the main risk factor for atherosclerotic cardiovascular disease. The aim of this paper is to assess the effect of monoclonal antibodies on lipid and lipoprotein metabolism in real-world practice. RECENT FINDINGS: The outcome trials showed effective reduction of LDL-C by 56-62%. Landmark studies enrolling over a total of 46,000 patients with CHD in their medical history demonstrated the beneficial effect of both agents on cardiovascular morbidity and mortality. The data from real everyday clinical practice are very limited or missing. Even in real-world practice, PCSK9 inhibitors have been shown to be an effective, safe, and well-tolerated class of drugs with effects comparable with those reported from large randomized controlled trials.
- 650 _2
- $a humanizované monoklonální protilátky $x farmakologie $7 D061067
- 650 12
- $a anticholesteremika $x farmakologie $x terapeutické užití $7 D000924
- 650 12
- $a kardiologie $7 D002309
- 650 12
- $a kardiovaskulární nemoci $x prevence a kontrola $7 D002318
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a PCSK9 inhibitory $7 D000091362
- 650 _2
- $a proproteinkonvertasa subtilisin/kexin typu 9 $x metabolismus $7 D000071449
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Todorovová, Veronika $u Center of Preventive Cardiology, 3rd Department of Internal Medicine, General University Hospital, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic
- 700 1_
- $a Šnejdrlová, Michaela $u Center of Preventive Cardiology, 3rd Department of Internal Medicine, General University Hospital, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic
- 700 1_
- $a Šatný, Martin $u Center of Preventive Cardiology, 3rd Department of Internal Medicine, General University Hospital, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic
- 700 1_
- $a Češka, Richard $u Center of Preventive Cardiology, 3rd Department of Internal Medicine, General University Hospital, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic
- 773 0_
- $w MED00186151 $t Current atherosclerosis reports $x 1534-6242 $g Roč. 24, č. 5 (2022), s. 357-363
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/35332442 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220720 $b ABA008
- 991 __
- $a 20220804134830 $b ABA008
- 999 __
- $a ok $b bmc $g 1822230 $s 1169778
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 24 $c 5 $d 357-363 $e 20220325 $i 1534-6242 $m Current atherosclerosis reports $n Curr Atheroscler Rep $x MED00186151
- LZP __
- $a Pubmed-20220720
